Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 21, 2018

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Thyroid CarcinomaMetastatic Thyroid Carcinoma
Interventions
DEVICE

PET/CT Scan

Up to four whole-body PET scans (approximately 24, 48, and 120 hours post 124I oral dose) will be performed on one of the GE Discovery 710 or 690 PET scanners.

DRUG

Iodine-124

Patients will receive 0.9 mg injections of rhTSH on two consecutive days. Twenty-four hours after the last injection of rhTSH each patient will receive approximately 5 mCi (range: 4-7 mCi) of 124I orally as a single dose. (If a holiday is present in the work week, 124I can be administered orally on Day 2, if needed).

Trial Locations (2)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

NOT_YET_RECRUITING

Weill Cornell Medical Center, New York

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER